Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

Kim, Stefano; Ghiringhelli, Francois; de la Fouchardière, Christelle; Evesque, Ludovic; Smith, Denis; Badet, Nicolas; Samalin, Emmanuelle; Lopez-Trabada Ataz, Daniel; Parzy, Aurelie; Desramé, Jérôme; Baba Hamed, Nabil; Buecher, Bruno; Tougeron, David; Bouché, Olivier; Dahan, Laetitia; Chibaudel, Benoist; El Hajbi, Farid; Mineur, Laurent; Dubreuil, Olivier; Ben Abdelghani, Meher; Pecout, Solange; Bibeau, Frederic; Herfs, Michael; Garcia, Marie-Line; Meurisse, Aurelia; Vernerey, Dewi; Taïeb, Julien; Borg, Christophe

doi:10.1016/s1470-2045(24)00081-0

The Lancet Oncology

2024

DOI: 10.1016/s1470-2045(24)00081-0

|View full text |Cite

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

Stefano Kim,

Francois Ghiringhelli,

Christelle de la Fouchardière

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance

Jayakrishnan,

Yadav,

Huffman

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance

Jayakrishnan,

Yadav,

Huffman

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

Actualités 2024 par le Comité de rédaction du Bulletin du Cancer : congrès ASCO, ESMO et au-delà

Vignot,

Bellesoeur,

Bouleuc

et al. 2024

Bulletin du Cancer

View full text Add to dashboard Cite

Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma

He,

Chen,

Yao

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

Cited by 6 publications

References 28 publications

Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance

Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance

Actualités 2024 par le Comité de rédaction du Bulletin du Cancer : congrès ASCO, ESMO et au-delà

Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma

Contact Info

Product

Resources

About